// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























387 Abstracts

Urinary N-terminal Fragment of Titin Predicts Mortality in Dilated Cardiomyopathy

Yu Sato - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Importance of Multiple Biomarker Approach in Patients With Cardiac Sarcoidosis

Takatoyo Kiko - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

Interleukin

Multicenter Randomized Controlled Trial Between Febuxostat and Allopurinol in Chronic Heart Failure Patients With Hyperuricemia

Satoshi Suzuki - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

Allopurinol

Identifying Heart Failure Using EMR-based Algorithms

Geoffrey H Tison - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Clinical Significance of Get With the Guidelines-Heart Failure Risk Score in Heart Failure Patients After Hospitalization

Satoshi Suzuki - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Clinical Significance of Re-worsening Left Ventricular Function in Patients With Dilated Cardiomyopathy

Takeru Nabeta - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Associations Between Testosterone Levels and Mortality in Male Patients With Heart Failure

Satoshi Suzuki - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Increased Resting Heart Rate on Electrocardiogram Compared to Pulse Rate Measured In-Office Indicates Potential Cardiac Overload: The J-hop Study

Yusuke Oba - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Heart Failure Epidemiology, Risk Factors and Mortality Risk by Gender in Community Cohorts Across Europe

Christina Magnussen - American Heart Association (AHA) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Prevalence and Significance of Right Ventricular FDG Uptake in Patients With Cardiac Sarcoidosis

Kenji Yodogawa - American Heart Association (AHA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

Angiotensin II

Relation of Systolic Blood Pressure on the Next Day to Post Discharge Mortality in Hospitalized Heart Failure Patients With Preserved Ejection Fraction - A Report From the JASPER Registry

Yu Sato - American Heart Association (AHA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Mitochondrial Related Intragraft Gene Expression During Acute Rejection After Heart Transplantation

Erick S Romero - American Heart Association (AHA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Prognostic Impact of Moderate Mitral Regurgitation on Hospitalized Heart Failure Patients With Preserved Ejection Fraction -A Report From the Jasper Registry-

Masayoshi Oikawa - American Heart Association (AHA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Prognostic Impact of Restless Legs Syndrome on Hospitalized Heart Failure Patients

Tomofumi Misaka - American Heart Association (AHA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

N/A

Change in Left Ventricular Ejection Fraction and Its Impact on Prognosis in Heart Failure Patients With Mid-Range Ejection Fraction

Yusuke Kimishima - American Heart Association (AHA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Utility of B-Type Natriuretic Peptide for Detecting Cardiac Amyloidosis in AL Amyloidosis

Yusuke Kimishima - American Heart Association (AHA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Lanthanum carbonate

Determinants of Exercise Tolerance in Patients With Non-Ischemic Heart Failure and Mid-Range Ejection Fraction as Assessed by Cardiopulmonary Exercise Testing

Ken Harada - American Heart Association (AHA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Characteristics and Outcomes of Recovered Left Ventricular Ejection Fraction in Heart Failure Patients With Reduced Ejection Fraction

Yusuke Kimishima - American Heart Association (AHA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Soluble Neprilysin Does Not Correlate With Outcome in Hypertrophic Cardiomyopathy

Tetsuro Yokokawa - American Heart Association (AHA) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Plasma Levels of Melatonin in Dilated and Hypertrophic Cardiomyopathies

Tomofumi Misaka - American Heart Association (AHA) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Melatonin

Copyright © 2026. QuantiNova All rights reserved